Clinical trials: Auto Immune Disease
Type 1 Diabetes, Diabetes, Autoimmune
Characteristics of Young-onset Diabetes in Sub-Saharan Africa (YODA) Study
Type 1 diabetes has been poorly characterised, with very sparse information available in the literature about the characteristics of the disease in Africa.
- Trial name
- YODA (NCT05013346)
- Testing
- No intervention needed
- Where
- 4 sites in Cameroon, South Africa and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Yaounde Central Hospital
Autoimmune Encephalitis, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)
Validation of a Diagnostic Score for Encephalitis to Assess the Risk of Autoimmune Origin
The investigators wish to test a diagnostic risk score for autoimmune encephalitis in case of encephalitis, previously validated by two American teams, in a retrospective analysis, according to the clinical and paraclinical data…
- Trial name
- Val-Dia score (NCT05953974)
- Testing
- Clinical score of Granillo and al.
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Hospices Civils de Lyon
Type 1 Diabetes
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
Type 1 diabetes (T1D) is caused by the destruction of insulin-producing cells by effector T cells (Teffs), due to a deficiency of regulatory T cells (Tregs).
- Trial name
- DF-IL2-REP (NCT05153070)
- Testing
- Cyclosporin, ILT101
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ovarian Cysts, Chronic Renal Insufficiency
Anti-inflammatory Cells in Peritoneal Cavity
Some subsets of lymphocytes are able to inhibit immune response and thus, could be used to control auto-immune diseases and transplant reject.
- Trial name
- NCT03189316
- Testing
- peritoneal fluid and blood sample
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Montpellier
Gastrointestinal Motility Disorder, Gastroparesis
IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy
Patients with the symptoms of generalized GI dysmotility, including gastroparesis, are sometimes refractory to available medications, devices and other interventions/ Some of these patients have serologic and/or endo organ…
- Conditions
- Gastrointestinal Motility Disorder, Gastroparesis, Neuropathy
- Trial name
- GAIN (NCT04208828)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Louisville
Systemic Juvenile Idiopathic Arthritis
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
This was a phase III study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in Japanese patients with Systemic Juvenile…
- Trial name
- NCT02396212
- Testing
- Canakinumab
- Where
- 7 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
The investigators hypothesize that prophylactic E-selectin inhibition via administration of uproleselan during melphalan conditioning will reduce the gastrointestinal (GI) toxicity in multiple myeloma (MM) patients undergoing…
- Trial name
- NCT04682405
- Testing
- Uproleselan, Melphalan
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Washington University School of Medicine
Healthy Volunteer, Rheumatoid Arthritis
Phenomics in Autoimmune and Inflammatory Diseases
The family of inflammatory/autoimmune systemic diseases (IAD) form a continuum from pure inflammatory diseases to pure autoimmune diseases, encompassing a large panel of inflammatory diseases with some autoimmune components, and…
- Conditions
- Healthy Volunteer, Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome
- Trial name
- TRANSIMMUNOM (NCT02466217)
- Testing
- 1: AID groups, 2: Control groups
- Where
- 2 sites in France
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
To evaluate toxicity profile and efficacy of a tandem autologous-nonmyeloablative transplant approach in newly diagnose myeloma patients younger than 65 years
- Trial name
- NCT00702247
- Testing
- Hematopoietic Stem Cell Transplantation
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
HLA/AAV Sensitization, Auto-immune Diseases
Real-world Clinical Effectiveness & Safety LV009, an in Vivo CAR-T for the Treatment of Hematologic Cancers, Auto-immune Diseases & HLA/ AAV Sensitization.
The study objective is to determine the real-world safety and effectiveness of LV009 therapy for 3 potential indications: (1) refractory or relapsed hematologic cancers (acute lymphoblastic Leukemia, B cell Lymphomas, multiple…
- Conditions
- HLA/AAV Sensitization, Auto-immune Diseases, Hematologic Cancers
- Trial name
- LV009 (NCT07873476)
- Testing
- LV009
- Where
- Indonesia
- Volunteers
- 100 people
- Sponsor
- Healthy Malaysia Association
Still's Disease, Adult-Onset
Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease
The objective of this study is to assess safety, tolerability and early signs of efficacy of the investigational drug Tadekinig alfa in Adult-onset Still's disease, a rare polygenic auto-inflammatory disorder for which treatment…
- Trial name
- NCT02398435
- Testing
- Tadekinig alfa (recombinant human IL-18 binding protein)
- Where
- 20 sites in France, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- AB2 Bio Ltd.
Immune Thrombocytopenia (ITP)
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.
- Trial name
- NCT01054443
- Testing
- Lusutrombopag
- Where
- 19 sites in United States
- Volunteers
- 20 people
- Sponsor
- Shionogi
Non-Hodgkin's Lymphoma (NHL)
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
According to amendment 3 this study addresses the question if intensification of administration of rituximab in standard treatment for patients with newly diagnosed aggressive B-Non Hodgkin Lymphoma (B-NHL) and high risk (aaIPI 2…
- Trial name
- NCT00129090
- Testing
- R-CHOEP 14 with 12x Rituximab
- Where
- Germany
- Volunteers
- 450 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Autoimmune Diseases
Lymphocyte Sub-populations and Auto Immune Diseases
To determine if artificial intelligence allow to detect lymphocyte subpopulations specific of diseases (such as primary Sjogren' syndrome and systemic lupus erythematosus) among patients with suspicion of autoimmune diseases.
- Trial name
- SPLIT (NCT03901664)
- Where
- France
- Volunteers
- 3,500 people
- Sponsor
- University Hospital, Brest
Rheumatoid Arthritis
Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes
The purpose of this study is to determine the preference of RA patients for the new Enbrel® (etanercept) pre-filled syringe in patients who are already taking Enbrel®.
- Trial name
- NCT00094341
- Testing
- Etanercept
- Volunteers
- 215 people
- Sponsor
- Amgen
Paraneoplastic Neurological Syndrome, Autoimmune Encephalitis
New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis.
- Trial name
- DeNobio (NCT05728931)
- Testing
- Test of biological samples
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Hospices Civils de Lyon
Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade
Tandem Auto-Allo Transplant for Lymphoma
Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma after autologous transplantation. Non-myeloablative allogeneic transplantation allows patients to receive an infusion of donor cells in…
- Conditions
- Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT01181271
- Testing
- Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant)
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Systemic Lupus Erthematosus, Auto Immune Disease
A Study of GR1803 in Systemic Lupus Erythematosus
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
- Trial name
- NCT07348055
- Testing
- GR1803 injection
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Nausea, Vomiting
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
The purpose of this study is to determine the efficacy of aprepitant in preventing acute and delayed chemotherapy induced nausea and vomiting when administered in combination with intravenous or oral ondansetron and intravenous…
- Trial name
- NCT00314743
- Testing
- Ondansetron, Dexamethasone, Aprepitant
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma
BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of BUCY+VP-16 and BUCY myeloablative conditioning regimens in diffuse large B-cell lymphoma undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma, Conditioning
- Trial name
- NCT03229616
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Nanfang Hospital, Southern Medical University